Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease
The Phase I trial of ENERGI-F705PD tablet was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetics of the investigational drug in 24 healthy subjects. The results confirmed the favorable safety and tolerability profile of ENERGI-F705PD and successfully validated its sustained-release oral formulation. Energenesis plans to advance ENERGI-F705PD into a Phase II trial....
ASPIRE for Lung Cancer launches the APAC Lung Cancer Policy Consensus as a regional call to action for improved lung cancer care
SINGAPORE, Aug. 1, 2025 /PRNewswire/ -- On 31st July 2025, a unified consensus document for improving lung cancer care in the Asia-Pacific (APAC) region was officially launched in Singapore, marking a pivotal moment in the regional fight against lung cancer. This represents the first comprehensive consensus for the region, an evidence-based agreement between stakeholders across the healthcare ecosystem that...
GenScript Biotech’s MSCI ESG Rating Upgraded to AA, Recognized as a Global Leader
PISCATAWAY, N.J., Aug. 1, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a leading global provider of life science research and manufacturing services, today announced that its ESG rating has been upgraded to AA from A by MSCI in recognition of the company's excellence in the areas of product safety & quality and human capital development, as well as continuous improvement...
Medit to Reveal New Medit i900 Mobility, Powered by True Mobility
SEOUL, South Korea, Aug. 1, 2025 /PRNewswire/ -- Medit (www.medit.com), a global leader in digital dentistry, today introduces the Medit i900 Mobility, a next-generation intraoral scanner designed to deliver simplicity and true mobility to clinical workflows. Medit to Reveal New Medit i900 Mobility, Powered by True Mobility The Medit i900 Mobility is...
Norgine welcomes PBS listing in Australia of IFINWIL® (eflornithine) for patients with high-risk neuroblastoma (HRNB)
This news is for Australian Media only Eflornithine is now reimbursed by the government under Australia's Pharmaceutical Benefits Scheme (PBS). The Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of eflornithine for post-maintenance treatment to prevent relapse in patients with high-risk neuroblastoma (HRNB) who are in remission after receiving multiagent, multimodality therapy.1 Approximately...
OSR Holdings Provides Transparency Update on Equity Financing Instruments
BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovation approaches to health and wellness to support global health outcomes, today provided a transparency update regarding its Equity Line of Credit (ELOC) agreement with White Lion GBM Innovation Fund and related convertible...
Neurophet Showcases Full-Cycle Brain Imaging Analysis Solutions for Alzheimer’s disease Including ‘Neurophet AQUA AD’ at AAIC 2025
Showcased brain imaging analysis products such as Neurophet AQUA AD, capable of monitoring side effects of Alzheimer's disease treatments Engaged in partnering with global big pharma and neurology KOLs, seeking global development collaborations for key products SEOUL, South Korea, July 31, 2025 /PRNewswire/ -- Neurophet (Co-CEOs Jake Junkil Been and Donghyeon...
NYSE Content Advisory: Pre-market update + Figma valued at over $19 billion in IPO
NEW YORK, July 31, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content Advisory: Pre-market update + Figma valued at over $19 billion...
RESEARCH ADVANCES FROM THE 2025 ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE
TORONTO, July 31, 2025 /PRNewswire/ -- New research results reported at the Alzheimer's Association International Conference® 2025 (AAIC®) advanced scientific understanding of risk, diagnosis and treatment of Alzheimer's disease and other dementias. Highlights include: Two lifestyle interventions in the U.S. POINTER clinical trial improved cognition in older adults at risk of...
Alphamab Oncology Announces Anti-HER2 Biparatopic ADC JSKN003 Received U.S. FDA IND Approval to Initiate a Phase II Clinical Study for Platinum-Resistant Ovarian Cancer
SUZHOU, China, July 31, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical study in the United States (study number: JSKN003-202) for the treatment of platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube...
